Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Other Working Capital Changes (2020 - 2025)

Xeris Biopharma Holdings (XERS) has disclosed Other Working Capital Changes for 6 consecutive years, with $3.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Working Capital Changes rose 1050.58% year-over-year to $3.3 million, compared with a TTM value of $2.1 million through Dec 2025, up 94.17%, and an annual FY2025 reading of $2.1 million, up 94.17% over the prior year.
  • Other Working Capital Changes was $3.3 million for Q4 2025 at Xeris Biopharma Holdings, up from $649000.0 in the prior quarter.
  • Across five years, Other Working Capital Changes topped out at $7.5 million in Q3 2023 and bottomed at -$3.3 million in Q4 2021.
  • Average Other Working Capital Changes over 5 years is $343473.7, with a median of -$188000.0 recorded in 2023.
  • The sharpest move saw Other Working Capital Changes crashed 549.45% in 2021, then surged 1088.3% in 2024.
  • Year by year, Other Working Capital Changes stood at -$3.3 million in 2021, then surged by 72.67% to -$899000.0 in 2022, then surged by 199.33% to $893000.0 in 2023, then plummeted by 138.3% to -$342000.0 in 2024, then surged by 1050.58% to $3.3 million in 2025.
  • Business Quant data shows Other Working Capital Changes for XERS at $3.3 million in Q4 2025, $649000.0 in Q3 2025, and -$270000.0 in Q2 2025.